Liquidia Corporation (LQDA)
Market Cap | 459.85M |
Revenue (ttm) | 13.79M |
Net Income (ttm) | -46.05M |
Shares Out | 64.50M |
EPS (ttm) | -0.82 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 625,229 |
Open | 7.13 |
Previous Close | 7.01 |
Day's Range | 7.06 - 7.37 |
52-Week Range | 3.26 - 8.79 |
Beta | 0.13 |
Analysts | Buy |
Price Target | 13.41 (+88.08%) |
Earnings Date | Mar 16, 2023 |
About LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina. [Read more]
Financial Performance
In 2021, Liquidia's revenue was $12.85 million, an increase of 1637.81% compared to the previous year's $739,628. Losses were -$34.58 million, -42.14% less than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for LQDA stock is "Buy." The 12-month stock price forecast is $13.41, which is an increase of 88.08% from the latest price.
News

Strength Seen in Liquidia Technologies, Inc. (LQDA): Can Its 9.7% Jump Turn into More Strength?
Liquidia Technologies, Inc. (LQDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furthe...

Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (‘793 Patent)
MORRISVILLE, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced that the PTAB has reaffirmed its original decision in the ‘793 IPR, which f...

Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
MORRISVILLE, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 10,000 shares of Liquidia...

Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million
MORRISVILLE, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that it has entered into a Revenue Interest Financing Agreement with ...

Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)
MORRISVILLE, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today a collaboration with Sandoz Inc. (Sandoz) and Mainbridge Health Partn...

Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 153%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 153.2% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is que...

Is Liquidia Technologies (LQDA) Stock Outpacing Its Medical Peers This Year?
Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.

Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 22.22% and 9.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...

Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Company to host webcast and conference call today at 8:30 a.m. ET Company to host webcast and conference call today at 8:30 a.m. ET

ANAVASI DIAGNOSTICS ANNOUNCES NEWLY ELECTED OUTSIDE BOARD OF DIRECTORS
The New Board Members Will Bring Industry Experience to Contribute to Company Growth WOODINVILLE, Wash. , Nov. 2, 2022 /PRNewswire/ -- Anavasi Diagnostics ('Anavasi'), an NIH/RADx medical technology c...

Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022
MORRISVILLE, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022. The ...

Precedential Opinion Panel Denies United Therapeutics' Request for Review of ‘793 Inter Partes Review Decision
MORRISVILLE, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on October 26, 2022, the Precedential Opinion Panel (POP) of the United States Patent and ...

Liquidia Announces Presentations at the CHEST 2022 Annual Meeting
MORRISVILLE, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of data related to the investigational use of YU...

7 Momentum Stocks to Buy Now for Extraordinary Gains
Before jumping directly into momentum stocks worth buying now, it's important to understand what momentum trading is. As the name implies, momentum trading relies on reacting to the current movement o...

Liquidia Provides Update on Hatch-Waxman Litigation and to Host Call on September 1, 2022, at 8:00am E.T.
MORRISVILLE, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that a ruling was issued by Judge Andrews, who is presiding over the litigation filed by United...

Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year?
Here is how Liquidia Technologies, Inc. (LQDA) and PolyPid Ltd. (PYPD) have performed compared to their sector so far this year.

Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 136%: Here's is How to Trade
The mean of analysts' price targets for Liquidia Technologies, Inc. (LQDA) points to a 136.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agr...

Find Highly-Ranked Cheap Stocks Under $10 to Buy with this Screen
We used one of our Zacks screens to help show investors how to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying as we start to close out August.

Here's Why Liquidia Technologies, Inc. (LQDA) is a Great Momentum Stock to Buy
Does Liquidia Technologies, Inc. (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 74%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 74.1% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is ques...

Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 37.50% and 11.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the st...

Liquidia Reports Second Quarter 2022 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the second quarter ended June 30, 2022. The ...

Liquidia to Report Second Quarter 2022 Financial Results on August 11, 2022
MORRISVILLE, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2022 financial results on Thursday, August 11, 2022. The...

Liquidia Announces the Publication of Long-Term Clinical Data from Completed INSPIRE Study in the Journal Pulmonary Circulation
MORRISVILLE, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the publication of clinical data from the completed INSPIRE study evaluating YUTREPIA™ (trepros...